OncoTargets and Therapy (Sep 2019)
Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy
Abstract
Jennifer Girard, John Reneau, Sumana Devata, Ryan A Wilcox, Mark S Kaminski, Jessica Mercer, Shannon Carty, Tycel J Phillips Department of Internal Medicine, Division of Hematology-Oncology, Rogel Cancer Center University of Michigan, Ann Arbor, MI, USACorrespondence: Tycel J PhillipsDepartment of Internal Medicine, Division of Hematology-Oncology, Rogel Cancer Center University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USATel +1 734 232 2883Email [email protected]: Mantle cell lymphoma (MCL) is an incurable intermediate-grade lymphoma representing 5–6% of non-Hodgkin’s lymphomas diagnosed in the United States. The introduction of inhibitors of Bruton’s tyrosine kinase (BTK) into targeted therapy for MCL has significantly improved outcomes in patients with relapsed/refractory (R/R) disease. Since the initial approval of the first-generation inhibitor, ibrutinib, several second-generation inhibitors have been explored. Acalabrutinib, a second-generation BTK inhibitor, has demonstrated impressive efficacy in clinical trials along with a safety profile that thus far appears improved compared to ibrutinib. The results of a Phase II trial in patients with R/R MCL led to the approval of acalabrutinib in this patient population while fueling further exploration of acalabrutinib in several ongoing clinical trials.Keywords: mantle cell lymphoma, Bruton’s tyrosine kinase, long-term safety, combinations
